GORDON CROFOOT: Open Payments
NPI 1730381005 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$6,550 in 111 payments from 15 companies in 2025. Trend: 2023 $2,468 · 2024 $1,905 · 2025 $6,550
Consulting: $3,440Food & beverage: $2,647Travel & lodging: $463
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC | 9 | $4,149 |
| ViiV Healthcare Company | 42 | $994 |
| Gilead Sciences, Inc. | 21 | $632 |
| Novo Nordisk Inc | 11 | $181 |
| Theratechnologies Inc. | 5 | $132 |
| Lilly USA, LLC | 6 | $125 |
| EMD Serono, Inc. | 4 | $101 |
| Napo Pharmaceuticals Inc | 5 | $94 |
| Antares Pharma, Inc. | 2 | $36 |
| PFIZER INC. | 1 | $20 |
Products named: CABENUVA, PIFELTRO, APRETUDE, RUKOBIA, EGRIFTA, MOUNJARO, Wegovy, Mytesi.
Industry payments across TX — which companies pay providers there.
